美股异动 | Moderna(MRNA.US)涨超6.7% CDC新规称接种新冠疫苗将基于个人决定

智通财经
Oct 08

智通财经APP获悉,周三,Moderna(MRNA.US)股价走高,截至发稿,该股涨超6.7%,报29.17美元。消息面上,美国疾病控制与预防中心(CDC)公布最新成人与儿童免疫接种计划,首次将新冠疫苗纳入“个体化决策”模式,并建议幼儿单独接种水痘疫苗,而非与麻疹、腮腺炎及风疹疫苗联合接种。CDC代理主任兼卫生与公共服务部副部长Jim O’Neill表示,新政策“让知情同意重回医疗实践”。他指出,2022年的普遍接种建议抑制了医生与患者讨论疫苗风险与收益的空间。新规强调,65岁以下群体中仅高风险人群的新冠疫苗收益更大,低风险者可与医生共同决定是否接种。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10